perceived potential benefits and challenges of e-detailing.
The following additional topics were covered if an e-detailing project was planned or had already been conducted (in three out of five cases): From four out of these five interviews, detailed case studies were written which were reviewed by the interviewees. This paper is structured as follows. The next section promotes the adoption of new marketing channels for pharmaceutical companies by showing typical shortcomings of conventional detailing. A definition of e-detailing as well as an overview of common edetailing approaches in the USA are then offered. The transferability of these approaches to the European market is examined by discussing their potential benefits and challenges. The paper concludes by discussing managerial implications.
CHALLENGES IN CONVENTIONAL DETAILING
As in other sectors, the efforts of pharmaceutical companies to identify profitable customers and retain their loyalty come under the heading of customer relationship management (CRM). The most important marketing tool in the area of prescription drugs is detailing, where field sales staff call on doctors at their practices or at hospitals to promote the sale of their products. Measured as a percentage of total marketing expenditure in the pharmaceutical industry, the costs of detailing in the USA are estimated at between 45 per cent 2 and 70 per cent. 3 In Europe, that percentage is significantly higher as there is no direct-to-consumer marketing.
The number of pharmaceutical field sales staff has shown constant growth over the past few years, doubling in the USA, for example, to around 80,000 between 1995 and 2001. 4 This has resulted in an increasing number of pharmaceutical representatives trying to market their products to doctors, which further aggravates the existing problems with detailing. While the underlying situation may be slightly different in Europe, pharmaceutical companies there are also looking for new ways of marketing their products to doctors due to several challenges in conventional detailing: [5] [6] [7] .
Limited opportunities for personal calls. is successful. 8 In some regions, the large distances involved restrict the number of personal calls which can be made to doctors.
. Large intervals between sales calls. The low visit frequency associated with the limited opportunities for personal calls mean that it may well be several months after the launch of new products that a pharmaceutical representative is able to present them to the doctor.
. Short call duration. In the USA, detailing visits last on average between three and four minutes; in Europe (UK) around nine minutes. 9 These lengths of time are inadequate to provide a doctor with a comprehensive product presentation.
. High costs. High costs associated with travelling and waiting time mean that an effective hour of detailing time incurs costs of up to £625 in the UK 10 and US$2,000 in the USA.
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Inadequate availability of on-the-spot information. When pharmaceutical representatives call on doctors they frequently have insufficient information material with them or lack the background knowledge to answer all the doctor's questions. While this may lead to useful follow-on contacts, it also means undesirable delays in the information flow or unnecessary extra work for the representative or call centre. In view of the fact that the content of details and the timing of their release are mainly decided by the marketing department or the pharmaceutical representative, the doctor has little opportunity to influence the information flow.
. Lack of differentiation from competitors. The large number of mergers and acquisitions in the pharmaceutical sector in recent years means that doctors frequently no longer know which corporation markets which products. At the same time, an ever increasing number of pharmaceutical representatives are presenting what are often similar products from different suppliers. This makes it all the more difficult for manufacturers to differentiate their products effectively from those of their competitors. 
Standardisation in communication.
In the case of conventional detailing, the personality and knowledge of the pharmaceutical representative are of great significance. While these aspects constitute an advantage for detailing calls, they also make it difficult for the pharmaceutical companies to ensure that their marketing messages are communicated in the same way throughout the market.
. Tendency to classify the doctors visited incorrectly. Success measurement in field sales is usually based on visit targetspharmaceutical representatives categorise the doctors they look after according to their potential for prescribing drugs (A, B, C customers) and have to achieve a minimum number of visits per year for each category. As 'C' doctors tend to be easier to visit, there is a tendency to classify them incorrectly. This leads to inefficiencies in sales and marketing activities.
E-DETAILING APPROACHES
Definition of e-detailing E-detailing denotes the use of information technology (IT) for promotional activities which provide customers (doctors, medical staff and patients) with information on pharmaceutical products. The aim of edetailing is to provide electronic support for and/or extend the established practice within the pharmaceutical sector of calling on doctors to promote pharmaceutical products. E-detailing can include the use of electronic channels for customer interaction as well as electronic support for sales representatives in their detailing calls, for example by providing them with electronic detailing aids or presentation material.
Forms of e-detailing
In practice, different approaches to edetailing have developed, which can be distinguished on the one hand by the type of interaction used to communicate, and on the other by the means of communication used (see Figure 1) . A human-human interaction denotes an approach where a customer communicates directly with a representative from a pharmaceutical company. This may take place synchronously in real time (eg video conference, chat room) or asynchronously (eg e-mail correspondence). In the case of rule-based human-machine interaction, a customer interacts with a program which is able to respond to customer requirements on the basis of rules. An example is a product presentation on a website which contains different information depending on the specialist knowledge of the customer. With static human-machine interaction the information is not dependent on customer behaviour. Examples are product information on static websites or e-mail newsletters. These three types of interaction differ in terms of the flexibility of communication: the customer's scope for influencing the content of communication is greatest in the case of human-human interaction and virtually non-existent in the case of static human-machine interaction (users can only decide whether or not they wish to receive the information).
The listed communication channels internet PC, mobile devices (mobile telephones, personal digital assistants, pagers), interactive digital TV (IDTV), telephone and personal visit each support different forms of communication (synchronous communication in real time or time-delayed, asynchronous communication) and are also differentiated by their diffusion and availability among customers as well as by their mediarichness. 12, 13 Whereas the internet PC channel, for example, permits both synchronous (chat, video conference) and asynchronous (e-mail) forms of communication and, depending on equipment, the transmission of text, image, audio and animations, the conventional telephone channel is limited to synchronous communication with the transmission of audio information. Activities which concentrate on better support for a pharmaceutical representative's personal visit to the customer require the least amount of adaptation on the part of the customer. In comparison with the other channels, the personal visit provides the best means of building up a personal relationship thanks to its large communication bandwidth. In this respect, however, e-detailing activities contribute little to resolving the problems of conventional detailing.
Examples of existing e-detailing solutions
Of the e-detailing approaches shown in Figure 1 , the following five have established themselves alongside the static information on websites, particularly in the US market:
. Video detailing. Here, doctors communicate with the representatives of a pharmaceutical company using PCs with internet access, camera, sound card and microphone, and obtain advice on specific products, ask questions or call up additional information via a web interface. The major provider of video detailing solutions is the US company iPhysicianNet (www.iPhysicianNet.com) whose customer base includes amongst others Bristol Myers Squibb, Merck, Pharmacia, Aventis and Novartis. iPysicianNet operates a videoconferencing platform financed by the pharmaceutical companies and provides doctors with a PC plus internet connection free of charge. In return, the doctors agree to take part in one video detailing session a month with each of the participating pharmaceutical companies. Video detailing comes closest to personal face-to-face interaction because of the high proportion of analogue communication elements (image, speech, etc). Its broad mediarichness makes this form of electronic interaction well suited to knowledge transfer where complex issues are involved.
14 . Telephone co-browsing. As in the case of video detailing, telephone co-browsing entails real-time interaction between a pharmaceutical representative or call centre operative and a doctor, while the pharmaceutical representative has access to the doctor's PC by remote control. The doctor and the pharmaceutical representative can talk to one another via an internet-based telephone line (IP telephony) and view web-based content at the same time. In comparison with video detailing, this form of e-detailing occupies less communication bandwidth, but does not provide a picture of the interlocutor. Telephone co-browsing is used, for example, by Novartis in France.
. Scripted or virtual detailing. Here, doctors access web-based, interactive multimedia programs -a mixture of Flash-based online presentation and online training for a specific product. As a rule, the presentations last between four and eight minutes. Following the presentation, doctors usually have the possibility to call up additional information, order samples or contact a pharmaceutical representative. Solutions of this kind are provided by Lathian Systems (www.lathian.com), RxCentric (www.rxcentric.com) or Physicians Interactive (www.physiciansinteractive.com). They are used, for example, by Johnson&Johnson, Amgen, Aventis, Novartis and GlaxoSmithKline. The attractiveness of scripted detailing solutions lies primarily in all day, every day access for doctors and low variable costs for the pharmaceutical company. This makes them particularly well suited wherever there is a need to address a broad customer base. The use of interactive intelligent programs for customer self-service increases the amount of time and attention the visitor devotes to the web offering in comparison with static web pages. . e-mail. Personalised e-mail messages (textbased or in HTML format with images), tailored to suit the interests of the recipient, can be used for product promotion either as a marketing tool in their own right or as an integral part of other e-detailing solutions. In conjunction with e-detailing, pharmaceutical companies frequently use emails (as a rule, with the consent of the recipients) to send out invitations to visit web-based e-detailing programs. An example of a company which supplies the concept, performs the e-mail campaign and measures its success is Aptilon (www.aptilon.com).
E-DETAILING POTENTIAL BENEFITS AND CHALLENGES IN EUROPE
In spite of the different potential benefits e-detailing has to offer, European pharmaceutical companies in particular find themselves confronted with a series of challenges when it comes to trying to exploit those potential benefits. Table 1 lists the challenges in conventional detailing and the main potential benefits and challenges of edetailing in Europe as perceived by the interviewees. For reasons of confidentiality, the companies' names have been withheld.
Potential benefits
Studies on the quantitative effects of edetailing projects available to the general public have mostly been carried out or sponsored by solution providers and refer to the North American market. Independently sourced data exist on the system from iPhysicianNet used at Novartis where pharmaceutical representatives conduct 13 details with the video detailing solution (versus eight conventional details) on a daily basis, and have been able to discuss 2.7 (versus 1.6) products in each case. The costs of a detail were reduced to US$48 (versus US$106). 16 A study by the HyGro Group on the benefits of a scripted detailing program from Physicians Interactive, performed for a product already established in the market, showed an increase in the prescription rate from 3.2 to 9.8 per cent in four months with a test group, which took part in two e-detailing sessions. 17 Sixty-eight per cent of the doctors taking part rated the e-detailing program as better than a conventional detailing session. For scripted detailing in the case of doctors with a high prescription potential, the HyRo Group calculated a return on investment of 480 per cent (increase in prescriptions measured in relation to the program-development costs).
For reasons of confidentiality, the interviews yielded very little quantitative information on the effects of e-detailing. The measured (or anticipated) qualitative benefits of e-detailing stated by the interviewees included lower detail costs compared with the conventional approach as well as various benefits associated with a novel electronic customer interaction channel:
. Lower detail costs. The absence of travelling, waiting time and, in part, personnel expenses, means that it costs less to present products using electronic channels. Depending on the e-detailing approach used, the Forrester Group 18 calculated, for the USA, savings of between 25 and 90 per cent per product presentation compared with conventional detailing.
. Greater reach and interaction frequency. Doctors whose low prescription potential previously made visits an unprofitable proposition can now be addressed thanks to the lower costs involved. The flexibility of use and the greater depth of information can facilitate access to doctors who had previously rejected or limited visits from pharmaceutical representatives. possibilities for classifying customers. Electronic channels which incorporate a facility for user identification provide a source of additional information on doctors' interests. If information on a specific drug or area of therapy is accessed on the doctor's own initiative, this allows the pharmaceutical company to draw farther-reaching conclusions about his or her interests than when material is passively received from a pharmaceutical representative. In Europe, however, the evaluation and use of such information is restricted to a certain extent by data protection regulations.
. Synergy effects for conventional detailing. Edetailing is almost universally seen as a complement to conventional detailing rather than as a substitute for it. Examples where the potential for synergy exists include: obtaining customer information on one channel and using it on another; the pharmaceutical representative accessing content available on the internet when Higher customer acceptance. E-detailing solutions give doctors greater control over the time, place and content of the detail and allow them a more active role in obtaining information which actually interests them (information pull). Pharmaceutical companies hope that this will encourage greater openness towards the content communicated during the detail. Doctors appreciate the flexibility which e-detailing gives them and take advantage of what is has to offer, for example, access outside normal office hours.
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Greater depth and speed of information. Edetailing provides scope for multimedia product presentations, which may be made available to doctors at any time via electronic channels, and scope for straightforward links to further electronic information and services.
Challenges
Pharmaceutical companies find themselves confronted with a series of challenges when it comes to exploiting the potential benefits of e-detailing. Setting up edetailing channels means burdening the marketing budget with additional expenditure, at least in the medium term, while various market factors as well human resistance make the profitable use of new interaction channels difficult.
. Reduction in absolute marketing costs. The experience gained in projects and the results of interviews conducted show that electronic e-detailing channels will not replace conventional detailing involving personal visits to doctors, at least in the immediate future. Neither doctors nor pharmaceutical representatives want to go without personal face-to-face contact, and e-detailing activities run alongside traditional field visits. Therefore, contrary to ambitious expectations in the industry, 20 e-detailing activities will not reduce a pharmaceutical company's marketing and sales expenditure in the near future.
. Provider situation and market structure. Until now, the providers of e-detailing solutions and platforms have concentrated on the North American market. It is only recently that the appropriate solutions have become available in Europe. 21 The very heterogeneous structure of the European market in comparison with that in the USA adds an extra complication. The linguistic and cultural differences between the various regions in Europe limit the scope for achieving economies of scale through the reuse of existing electronic services.
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Legal restrictions. Statutory requirements and industrial codes of practice limit the possibilities for compensating doctors for using e-detailing. Payment and sponsoring models of the kind widely used in the USA are not transferable to Europe, which is why any profitability figures relating to edetailing from the USA are not very meaningful here. European companies face the challenge of finding alternative incentives which will encourage doctors to use their solutions. Differences are again to be found in the area of data protectionit is difficult for European companies to collect and evaluate certain personal information; in some situations they may only do so with the express consent of the doctors concerned.
. Internal scepticism and resistance. Field sales play an important role in most pharmaceutical companies and consequently wield a corresponding level of influence within the organisation. Fears related to job losses or unwelcome changes in working practices can cause resistance to new detailing solutions to build up either consciously or subconsciously in field sales, thus hindering any projects in this area.
. Mistrust/objectivity of information. More and more doctors have access to the internet and use it to search for medical information. 23, 24 Information provided by pharmaceutical companies, however, is frequently regarded with scepticism. According to a study by Forrester, 25 company-owned pharmaceutical websites rank bottom in the list of information sources used by doctors and considered to be valuable. Moreover, online information in general fails to rate as well as its offline equivalents. Doctors frequently state that they regard colleagues, medical books or journals as more independent and more significant for their own information requirements and for helping them to form opinions.
. Establishment/acceptance of new communication channels. The more complex forms of interaction such as video conferencing or telephone co-browsing require participants to take time to familiarise themselves with the technical environment as well as with the features and possibilities of electronic communication. 26, 27 The experience gained in e-detailing projects shows that confronting users with new and unfamiliar communication channels presents an initial barrier, which pharmaceutical companies have to overcome proactively (such as by providing user training). In addition, most European physicians are currently lacking the necessary infrastructure for certain edetailing approaches such as video detailing (PC with video camera and broadband internet access). Table 2 summarises the main potential benefits and challenges identified in connection with e-detailing.
CONCLUSIONS FOR PHARMACEUTICAL COMPANIES IN EUROPE
E-detailing will complement rather than replace conventional detailing. As a consequence, future-oriented marketing in the pharmaceutical industry requires coordinated online and offline channels. The main potential benefits of e-detailing are not to be found in the reduction of absolute marketing costs but in enhanced customer acquisition, selection and retention. In order to realise these potential benefits, pharmaceutical companies should ensure that they obtain valuable customer information via the electronic channels and also utilise it for all the other customer interaction channels.
Pharmaceutical companies should combine push and pull approaches when establishing edetailing channels. However, the European market is not yet ready for video detailing. Experience has shown that the initiative for establishing contact between pharmaceutical companies and doctors also has to come from the former in the case of e-detailing. 28 A mix of different push or pull approaches (such as a combination of e-mail newsletter and scripted detailing) can therefore be useful. Now, however, the video detailing approach would not be a viable option for most regions in Europe, due to a lack of collaboration platform providers such as those to be found in the USA, for example with iPhysicianNet, In the early phases of the lifecycle of pharmaceutical products, edetailing seems to meet with a higher level of acceptance among doctors as interest in and need for information is greater here than in the case of established products. 29, 30 Ultimately, however, the factors which determine success are the doctors' channel preferences and their willingness to adopt new technology.
While product information is essential, it is hardly going to be enough to motivate doctors to use e-detailing facilities. Pharmaceutical companies have to think of effective incentives for the use of e-detailing channels, such as a broader spectrum of services that support the doctors' business processes. The provision of effective incentive systems is a major challenge for e-detailing projects in Europe. The types of electronic interaction with the pharmaceutical company should therefore be expanded beyond straightforward product promotion to offer a broader spectrum of services and incentives geared to the doctors' customer process. The attractiveness of using such facilities can be enhanced, for example, by realising portalbased collaboration scenarios offering greater support for doctor-patientpharmaceutical company interaction, and thus ensuring that these services become more firmly embedded in doctors' day-today work processes.
The implementation of e-detailing requires coordinated change management. Successful project implementation calls for support both at management level and at the level of the pharmaceutical representatives. The latter play a crucial role in making doctors aware of the electronic services available. The management of change, open communication of the potential benefits and impacts of e-detailing activities and continuous measurement of success are therefore important factors which will decide the success of a project.
Integrated IT systems are a prerequisite for coordinated online and offline activities. Pharmaceutical companies have to integrate e-detailing channels in their CRM system landscape.
Online and offline activities have to be coordinated and integrated, which requires a suitable level of integration where the information systems involved are concerned (eg customer relationship and/or territory management systems, content management systems, etc).
